Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease

被引：31

作者：

Altmann, Vivian ^{[1
]}

Schumacher-Schuh, Artur F. ^{[2
]}

Rieck, Mariana ^{[1
]}

Callegari-Jacques, Sidia M. ^{[3
]}

Rieder, Carlos R. M. ^{[2
]}

Hutz, Mara H. ^{[1
]}

机构：

[1] Univ Fed Rio Grande do Sul, Inst Biociencias, Dept Genet, BR-90049 Porto Alegre, RS, Brazil

[2] Hosp Clin Porto Alegre, Serv Neurol, Porto Alegre, RS, Brazil

[3] Univ Fed Rio Grande do Sul, Dept Estat, Porto Alegre, RS, Brazil

来源：

PHARMACOGENOMICS | 2016年 / 17卷 / 05期

关键词：

algorithm; dopamine transporter; levodopa; Parkinson's disease; pharmacogenetics; synaptic vesicle isoform C; DOPAMINE TRANSPORTER GENE; SYNAPTIC VESICLE PROTEIN; BODY-WEIGHT; SV2C; PHARMACOKINETICS; LOCALIZATION; EXPRESSION; DYSKINESIA; BRAIN;

D O I：

10.2217/pgs.15.183

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Aim: Levodopa is first-line treatment of Parkinson's disease motor symptoms but, dose response is highly variable. Therefore, the aim of this study was to determine how much levodopa dose could be explained by biological, pharmacological and genetic factors. Patients & methods: A total of 224 Parkinson's disease patients were genotyped for SV2C and SLC6A3 polymorphisms by allelic discrimination assays. Comedication, demographic and clinical data were also assessed. Results: All variables with p < 0.20 were included in a multiple regression analysis for dose prediction. The final model explained 23% of dose variation (F = 11.54; p < 0.000001). Conclusion: Although a good prediction model was obtained, it still needs to be tested in an independent sample to be validated.

引用

页码：481 / 488

页数：8

共 35 条

[1] Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease
Arabia, G
Zappia, M
Bosco, D
Crescibene, L
Bagalà, A
Bastone, L
Caracciolo, M
Scornaienghi, M
Quattrone, A
[J]. NEUROLOGICAL SCIENCES, 2002, 23 (Suppl 2) : S53 - S54
[2] Controlled-protein dietary regimens for Parkinson's disease
Cereda, Emanuele
Barichella, Michela
Pezzoli, Gianni
[J]. NUTRITIONAL NEUROSCIENCE, 2010, 13 (01) : 29 - 32
[3] SV2 Renders Primed Synaptic Vesicles Competent for Ca2+-Induced Exocytosis
Chang, Wen-Pin
Suedhof, Thomas C.
[J]. JOURNAL OF NEUROSCIENCE, 2009, 29 (04) : 883 - 897
[4] The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa
Cilia, Roberto
Akpalu, Albert
Sarfo, Fred Stephen
Cham, Momodou
Amboni, Marianna
Cereda, Emanuele
Fabbri, Margherita
Adjei, Patrick
Akassi, John
Bonetti, Alba
Pezzoli, Gianni
[J]. BRAIN, 2014, 137 : 2731 - 2742
[5] Pharmacological Treatment of Parkinson Disease A Review
Connolly, Barbara S.
Lang, Anthony E.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (16): : 1670 - 1683
[6] A role for Sv2c in basal ganglia functions
Dardou, D.
Monlezun, S.
Foerch, P.
Courade, J-P
Cuvelier, L.
De Ryck, M.
Schiffmann, S. N.
[J]. BRAIN RESEARCH, 2013, 1507 : 61 - 73
[7] Distribution of SV2C mRNA and protein expression in the mouse brain with a particular emphasis on the basal ganglia system
Dardou, D.
Dassesse, D.
Cuvelier, L.
Deprez, T.
De Ryck, M.
Schiffmann, S. N.
[J]. BRAIN RESEARCH, 2011, 1367 : 130 - 145
[8] Parkinson's disease: Mechanisms and models
Dauer, W
Przedborski, S
[J]. NEURON, 2003, 39 (06) : 889 - 909
[9] Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease
Devos, David
Lejeune, Stephanie
Cormier-Dequaire, Florence
Tahiri, Khadija
Charbonnier-Beaupel, Fanny
Rouaix, Nathalie
Duhamel, Alain
Sablonniere, Bernard
Bonnet, Anne-Marie
Bonnet, Cecilia
Zahr, Noel
Costentin, Jean
Vidailhet, Marie
Corvol, Jean-Christophe
[J]. PARKINSONISM & RELATED DISORDERS, 2014, 20 (02) : 170 - 175
[10] Functional effects of dopamine transporter gene genotypes on in vivo dopamine transporter functioning: a meta-analysis
Faraone, S. V.
Spencer, T. J.
Madras, B. K.
Zhang-James, Y.
Biederman, J.
[J]. MOLECULAR PSYCHIATRY, 2014, 19 (08) : 880 - 889

← 1 2 3 4 →